Twinbeech Capital LP Uni Qure N.V. Transaction History

Twinbeech Capital LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$14.54 - $21.5 $500,946 - $740,739	-34,453 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$20.24 - $36.01 $697,328 - $1.24 Million	34,453 New	34,453 $715,000
Q3 2021 Nov 15, 2021	SELL	$26.01 - $38.22 $331,679 - $487,381	-12,752 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$29.97 - $37.17 $382,177 - $473,991	12,752 New	12,752 $393,000
Q1 2021 May 17, 2021	SELL	$29.24 - $42.03 $319,534 - $459,303	-10,928 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$35.35 - $50.67 $386,304 - $553,721	10,928 New	10,928 $395,000
Q3 2020 Nov 16, 2020	SELL	$35.98 - $47.66 $423,196 - $560,576	-11,762 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $30,325 - $45,589	-673 Reduced 5.41%	11,762 $530,000
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $497,524 - $919,816	12,435 New	12,435 $590,000

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.